DBV Technologies S.A. (DBVT)

NASDAQ: DBVT · IEX Real-Time Price · USD

5.11 -0.02 (-0.39%)

Sep 17, 2021 4:00 PM EDT - Market closed

Market Cap	570.16M
Revenue (ttm)	4.40M
Net Income (ttm)	n/a
Shares Out	109.93M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,793
Open	5.12
Previous Close	5.13
Day's Range	5.06 - 5.13
52-Week Range	1.35 - 7.38
Beta	2.23
Analysts	Buy
Price Target	10.99 (+115.1%)
Est. Earnings Date	n/a

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosi...

IndustryBiotechnology

Founded2002

CEODaniel Tasse

Employees97

Stock ExchangeNASDAQ

Ticker SymbolDBVT

Full Company Profile

Financial Performance

In 2020, DBVT's revenue was 11.28 million, a decrease of -23.33% compared to the previous year's 14.71 million. Losses were -159.56 million, -7.24% less than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 3 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is 10.99, which is an increase of 115.09% from the latest price.

Price Target

$10.99

(115.09% upside)

Analyst Consensus: Buy

DBV Technologies S.A. (DBVT)

About DBVT

Financial Performance

Analyst Forecast

News

DBV Technologies to Participate at Upcoming Investor Conferences

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

DBV Technologies to Present at Upcoming Investor Conferences

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. ...

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

DBV Technologies Reports Q1 2021 Financial Results

DBV Technologies to Participate in Upcoming Investor Conferences

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March...

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Febru...

Why DBV Technologies Stock Is Rising Today

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Janua...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF